YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Image source: The Motley Fool. DATE Thursday, August 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Ofer Gonen Chief Financial Officer - Hani Luxenburg Executive Vice President of Strategy and Corporate Development -…
MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarte…
* MediWound (MDWD [https://seekingalpha.com/symbol/MDWD]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.77 [https://seekingalpha.com/symbol/MDWD/earnings/esti…
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. Thi…
United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago. These figures are adjusted for non-recurring…
(RTTNews) - MediWound Ltd. (MDWD) reported its financial results for the first quarter of 2026, reflecting a revenue decline, and reaffirmed the full-year revenue guidance. Company Profile MediWound is a biopharmaceutical company focused o…
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quar…
Major earnings expected before the bell on Wednesday include: * PDD Holdings (PDD [https://seekingalpha.com/symbol/PDD]) * The Bank of Nova Scotia (BNS [https://seekingalpha.com/symbol/BNS]) * Bank of Montreal (BMO [https://seekingalpha.co…
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generatio…
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support ongoing VALUE Phase III study and planned ex…
MediWound Ltd. MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on…
MediWound logo Key Points EscharEx Phase III VALUE trial is advancing with the majority of ~40 U.S. and European sites enrolling toward a 216‑patient target and an interim sample‑size assessment after ~65% treated to preserve ~90% power; M…
MediWound Ltd. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Drivers The company successfully commissioned an expanded manufacturing facility, increasing NexoBrid production capacity sixfold to meet anticipated…
MediWound Ltd. MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expect…
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Millio…
Major earnings expected before the bell on Thursday include: * Walmart (WMT [https://seekingalpha.com/symbol/WMT]) * ZIM Integrated Shipping Services Ltd. (ZIM [https://seekingalpha.com/symbol/ZIM]) * NetEase (NTES [https://seekingalpha.co…
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago. These figures are adjusted for non-recurring items.…
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global l…
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of full operational readine…
MediWound (MDWD) “announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the…
* MediWound (NASDAQ:MDWD [https://seekingalpha.com/symbol/MDWD]) announced on Monday that it has entered into a definitive securities purchase agreement for the sale and purchase of 1.73 million ordinary shares of the company at $17.30 per…
MediWoundAnnounces$30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, to…
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, Septembe…
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, ho…
MediWound(NASDAQ:MDWD) reported fiscal second quarter 2025 results on Aug. 14, 2025, with revenue rising 43% quarter over quarter to $5.7 million, driven by higher product sales and a favorable mix. The company advanced its Phase III Escha…
MediWound Ltd (NASDAQ:MDWD [https://www.chartmill.com/stock/quote/MDWD]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $5.7 million, a 43% s…
* MediWound press release [https://seekingalpha.com/pr/20200736-mediwound-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:MDWD [https://seekingalpha.com/symbol/MDWD]): Q2 GAAP EPS of -$1.23 misses by $0…
MediWound Ltd. VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaboration…
September S&P 500 E-Mini futures (ESU25) are down -0.02%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are down -0.08% this morning, taking a breather after recent gains, while investors look ahead to crucial U.S. producer inflation data…
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are down -0.08% this morning…
Major earnings expected before the bell on Thursday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Deere & Company (DE [https://seekingalpha.com/symbol/DE]) * First Majestic Silver Corp. (AG [https://seekingalpha.com/symbol/…
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wou…
Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items…
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-gener…
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended M…
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaboratio…